Inventor · disambiguated record
Douglas Alan Lorenz
Also filed as: LORENZ DOUGLAS A · LORENZ DOUGLAS ALAN
26 granted patents·19 pending applications·148 citations·filing 1993–2024
95Inventor score
Top patents by PatentIndex Score
45 records- 0195US8202912B2Pharmaceutical compositions providing enhanced drug concentrationsCURATOLO WILLIAM J·Filed 2011·Granted Jun 19, 2012·29 cites·7 claims
- 0293US8026286B2Pharmaceutical compositions providing enhanced drug concentrationsBEND RES INC·Filed 2000·Granted Sep 27, 2011·36 cites·8 claims
- 0392US11839689B2Formulations of enzalutamideASTELLAS PHARMA INC·Filed 2022·Granted Dec 12, 2023·2 cites·7 claims
- 0489US12502357B2Formulations of enzalutamideASTELLAS PHARMA INC·Filed 2024·Granted Dec 23, 2025·0 cites·1 claims
- 0589US8372836B2Spray dried formulationBEND RES INC·Filed 2007·Granted Feb 12, 2013·8 cites·7 claims
- 0687US9468604B2Pharmaceutical compositions of dispersions of drug and neutral polymersBEND RES INC·Filed 2014·Granted Oct 18, 2016·3 cites·19 claims
- 0787US5288916AEnantiomeric resolution of 4-(3,4-dichlorophenyl)-3,4-dihydro-1(2H)-naphthalenoneBEND RES INC·Filed 1993·Granted Feb 22, 1994·29 cites·19 claims
- 0887US2025049721A1Formulations of EnzalutamideASTELLAS PHARMA INC·Filed 2024·Application pending·0 cites
- 0985US8501231B2Pharmaceutical compositions providing enhanced drug concentrationsCURATOLO WILLIAM J·Filed 2012·Granted Aug 6, 2013·5 cites·10 claims
- 1082US12447128B2Formulations of enzalutamideASTELLAS PHARMA INC·Filed 2022·Granted Oct 21, 2025·0 cites·4 claims
- 1182US8796341B2Pharmaceutical compositions providing enhanced drug concentrationsBEND RES INC·Filed 2013·Granted Aug 5, 2014·3 cites·8 claims
- 1281US7115279B2Pharmaceutical compositions of cholesteryl ester transfer protein inhibitorsCURATOLO WILLIAM J·Filed 2001·Granted Oct 3, 2006·13 cites·76 claims
- 1379US8980321B2Pharmaceutical compositions providing enhanced drug concentrationsBEND RES INC·Filed 2014·Granted Mar 17, 2015·2 cites·10 claims
- 1478US8389011B2Pharmaceutical compositions of cholesteryl ester transfer protein inhibitorsCREW MARSHALL D·Filed 2012·Granted Mar 5, 2013·3 cites·15 claims
- 1578US8048452B2Pharmaceutical compositions of cholesteryl ester transfer protein inhibitorBEND RES INC·Filed 2006·Granted Nov 1, 2011·2 cites·15 claims
- 1676US8197848B2Pharmaceutical compositions of cholesteryl ester transfer protein inhibitorsCREW MARSHALL D·Filed 2007·Granted Jun 12, 2012·2 cites·16 claims
- 1775US9918997B2Compositions and methods for the treatment of neurodegenerative and other diseasesREEDER THADDEUS CROMWELL·Filed 2017·Granted Mar 20, 2018·1 cites·11 claims
- 1874US7235259B2Pharmaceutical compositions of cholesteryl ester transfer protein inhibitorsPFIZER·Filed 2002·Granted Jun 26, 2007·8 cites·26 claims
- 1967US2020060976A1Formulations of enzalutamideASTELLAS PHARMA INC·Filed 2019·Application pending·0 cites
- 2065US2006216351A1Pharmaceutical Compositions of Dispersions of Drugs and Neutral PolymersPFIZER·Filed 2006·Application pending·0 cites
- 2164US9980978B2Compositions and methods for the treatment of neurodegenerative and other diseasesGLIALOGIX INC·Filed 2016·Granted May 29, 2018·0 cites·3 claims
- 2264US9974798B2Compositions and methods for the treatment of neurodegenerative and other diseasesGLIALOGIX INC·Filed 2016·Granted May 22, 2018·0 cites·8 claims
- 2364US2016374945A1Pharmaceutical compositions of dispersions of drug and neutral polymersBEND RES INC·Filed 2016·Application pending·0 cites
- 2464US2019209476A1Formulations of enzalutamideMEDIVATION PROSTATE THERAPEUTICS LLC·Filed 2018·Application pending·0 cites
- 2563US10398713B2Compositions and methods for the treatment of neurodegenerative and other diseasesGLIALOGIX INC·Filed 2018·Granted Sep 3, 2019·0 cites·11 claims
- 2662US7897175B2Dosage forms comprising a CETP inhibitors and an HMG-CoA reductase inhibitorBEND RES INC·Filed 2003·Granted Mar 1, 2011·2 cites·13 claims
- 2762US2014378517A1Formulations of enzalutamideBEND RES·Filed 2014·Application pending·0 cites
- 2861US9597339B2Compositions and methods for the treatment of neurodegenerative and other diseasesGLIALOGIX INC·Filed 2014·Granted Mar 21, 2017·0 cites·4 claims
- 2960US2017224624A1Formulations of enzalutamideBEND RES INC·Filed 2016·Application pending·0 cites
- 3059US9457095B2Pharmaceutical compositions providing enhanced drug concentrationsBEND RES INC·Filed 2015·Granted Oct 4, 2016·0 cites·9 claims
- 3159US2014179749A1Formulations of enzalutamideBEND RES·Filed 2013·Application pending·0 cites
- 3259US2014100256A1Formulations of enzalutamideBEND RES·Filed 2013·Application pending·0 cites
- 3359US2003091643A1Pharmaceutical compositions of dispersions of drugs and neutral polymersFiled 2002·Application pending·0 cites
- 3458US2017027910A1Formulations of enzalutamideBEND RES INC·Filed 2016·Application pending·0 cites
- 3555US2007287719A1Salts, Prodrugs and Formulations of 1-[5-(4-Amino-7-Isopropyl-7H-Pyrrolo[2,3-D]Pyrimidine-5-Carbonyl)-2-Methoxy-Phenyl]-3-(2,4-Dichloro-Phenyl)-UreaPFIZER·Filed 2006·Application pending·0 cites
- 3653US7655692B2Process for forming amorphous atorvastatinPFIZER·Filed 2004·Granted Feb 2, 2010·0 cites·14 claims
- 3751US2004185102A1Dosage forms comprising a CETP inhibitor and an HMG-CoA reductase inhibitorPFIZER·Filed 2003·Application pending·0 cites
- 3850US10098843B2Compositions of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidineCYMABAY THERAPEUTICS INC·Filed 2016·Granted Oct 16, 2018·0 cites·15 claims
- 3950US2006247272A14-Amino Substituted-2-Substituted-1,2,3,4-tetrahydroquinoline CompoundsPFIZER·Filed 2006·Application pending·0 cites
- 4048US2005129772A1Compositions comprising an HIV protease inhibitorAGOURON PHARMA·Filed 2004·Application pending·0 cites
- 4148US2006063803A14-Amino substituted-2-substituted-1,2,3,4-tetrahydroquinoline compoundsPFIZER·Filed 2005·Application pending·0 cites
- 4245US9241924B2Compositions of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidineMCWHERTER CHARLES A·Filed 2011·Granted Jan 26, 2016·0 cites·11 claims
- 4344US2008274192A1Pharmaceutical Compositions Comprising an Amorphous Form of a Vegf-R-InhibitorPFIZER·Filed 2006·Application pending·0 cites
- 4443US2001053791A1Glycogen phosphorylase inhibitorFiled 2001·Application pending·0 cites
- 4539US2001053778A1Pharmaceutical compositions of glycogen phosphorylase inhibitorsFiled 2001·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Douglas Alan Lorenz files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →